NASDAQ OMX

Karolinska Development company Umecrine Cognition to present at the EASL International Liver Congress 2017

Dela

STOCKHOLM - April 21, 2017. Karolinska Development's (Nasdaq Stockholm: KDEV) portfolio company Umecrine Cognition AB, whose novel orally-active GABA A receptor modulating steroid, GR3027, is in clinical development for hepatic encephalopathy (HE), will present clinical results from its Phase 1 study at The International Liver Congress TM 2017, the annual meeting of the European Association for the Study of the Liver, being held April 19-23, 2017, in Amsterdam, The Netherlands.

The poster, entitled "GR3027 reverses neurosteroid-induced GABAA receptor-mediated inhibition of brain function: A human challenge study", presents results of the human challenge part of the Phase 1a study designed to evaluate single-dose safety, tolerability and CNS target engagement of GR3027 in healthy adults. The challenge component involved a three-part cross-over design, in which healthy male subjects were randomized to receive placebo or two different doses of GR3027 prior to challenge. Its principle objective was to evaluate the ability of GR3027 to antagonize allopregnanolone-induced activation of GABAA as determined by its pharmacodynamic effects on two GABAA-modulated CNS functions, Saccadic Eye Velocity (SEV) and self-rated sedation using a Visual Analogue Scale (VAS).

Key findings presented in the poster include the following:

  • In predefined statistical analyses, GR3027 significantly inhibited the allopregnanolone-induced decrease in SEV (p=0.03; Wilcoxon Signed Rank Test); the results also provided evidence that GR3027 mitigates the impaired self-rated sedation produced by allopregnanolone.
  • In post-hoc statistical analyses that included only subjects who exhibited allopregnanolone-induced changes when pretreated with placebo, GR3027 significantly inhibited both the allopregnanolone-induced decrease in SEV (p=0.04; Wilcoxon Signed Rank Test) and allopregnanolone-induced sedation (p=0.01 and p=0.05 for low and high dose, respectively; Wilcoxon Signed Rank Test).

Enhanced GABAergic tone via neurosteroid-induced allosteric activation of GABAA receptors is emerging as critical to the pathogenesis of HE, prompting efforts to develop agents that antagonize GABAA receptor-potentiating neurosteroids [1]. GR3027, a novel orally active small molecule designed to reduce GABAA receptor mediated inhibition of brain function by antagonizing endogenous inhibitory neurosteroids such as allopregnanolone, has been shown to be effective in animal models of HE [2], and the present findings demonstrate its ability to modulate the function of CNS GABAA receptors in humans. A Phase 1b/2a clinical study designed to assess safety, tolerability and PK of multiple ascending doses in healthy adults and patients with cirrhosis as well as preliminary exploration of the effect of GR3027 on cognitive function in cirrhotics is underway.

The poster will be presented on Friday, April 21, 2017, in Hall 1 session Cirrhosis and its complications: Clinical aspects, RAI Amsterdam Convention Center.

For further information, please contact:

Jim Van heusden, CEO, Karolinska Development AB
Phone: +46 72 858 32 09, e-mail: jim.van.heusden@karolinskadevelopment.com 

Viktor Drvota, Deputy CEO and Chief Investment Officer, Karolinska Development AB
Phone: +46 73 982 52 02, e-mail: viktor.drvota@karolinskadevelopment.com

David Dible/Mark Swallow/Pip Batty, Citigate Dewe Rogerson
Phone: +44 20 7638 9571; e-mail: KDev@citigatedr.co.uk

About Umecrine Cognition AB
Umecrine Cognition's GR3027 represents a first-in-class product against a target that is implicated in several major CNS-related disorders, including HE, a potentially life-threatening disorder with high and growing unmet medical need. For more information, please visit www.umecrinecognition.com

[1] Butterworth RF. 2016.  Neurosteroids in hepatic encephalopathy: novel insights and new therapeutic opportunities. J Steroid Biochem Mol Biol., 160: 94-97. [2] Johansson M, Agusti A, Llansola M, Montoliu C, Strömberg J, Malinina E, Ragagnin G, Doverskog M, Bäckström T, Felipo V. GR3027 antagonizes GABAA receptor-potentiating neurosteroids and restores spatial learning and motor coordination in rats with chronic hyperammonemia and hepatic encephalopathy. Am J Physiol Gastrointest Liver Physiol. 2015; 309:G400-9

About Karolinska Development AB
Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences investment company. The company focuses on identifying breakthrough medical innovations in the Nordic region that are developed by entrepreneurs and leadership teams. The Company invests in the creation and growth of companies that advance these assets into commercial products that are designed to make a difference to patients' lives while providing an attractive return on investment to shareholders.

Karolinska Development has access to world-class medical innovations at the Karolinska Institutet and other leading universities and research institutes in the Nordic region. The Company aims to build companies around scientists who are leaders in their fields, supported by experienced management teams and advisers, and co-funded by specialist international investors, to provide the greatest chance of success.

Karolinska Development has established a portfolio of nine companies targeting opportunities in innovative treatment for life-threatening or serious debilitating diseases.

The Company is led by an entrepreneurial team of investment professionals with a proven track record as company builders and with access to a strong global network.

For more information, please visit www.karolinskadevelopment.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Karolinska Development AB (publ) via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Skriv in din e-postadress så får du ett mejl när vi har något nytt att berätta.

Senaste pressmeddelandena från NASDAQ OMX

Hitachi Vantara Unveils New Turnkey IoT Appliance, Powered by Lumada Software19.9.2017 17:50Pressmeddelande

Hitachi IoT Appliance Accelerates the Time to Insight and Value of IoT Solution Deployments for Industrial and Commercial Enterprise Customers LAS VEGAS, Sept. 19, 2017 (GLOBE NEWSWIRE) -- Hitachi Vantara, a wholly owned subsidiary of Hitachi, Ltd. (TSE:6501), today unveiled a new appliance for internet of things (IoT) deployments: Hitachi IoT Appliance, powered by Lumada, Hitachi's IoT platform. Delivered as a turnkey system, the appliance's "hyperconverged meets microservices" architecture combines Hitachi's best-in-class storage and compute with industry-leading networking technologies and comes fully integrated with Hitachi's latest Lumada software. Hitachi IoT Appliance has been fully pre-architected and pre-validated to provide a plug-and-play solution that can be easily deployed and production-ready in under an hour. This gives users the ability to more rapidly connect, monitor and extract actionable insights from their business and industrial assets. Fo

Hitachi Aims To Disrupt Industrial IoT Platform Market With New Commercial Lumada Software Stack19.9.2017 17:50Pressmeddelande

Fully Enhanced and Now Available as a Standalone Offering for IoT Developers and Architects, Hitachi's Lumada Provides an Intelligent, Composable Platform That Delivers Faster Time to Insight and Business Value for Industrial and Enterprise Customers TOKYO and LAS VEGAS, Sept. 19, 2017 (GLOBE NEWSWIRE) -- Hitachi Ltd. (TSE:6501) and Hitachi Vantara, today jointly announced Hitachi's first commercial Lumada internet of things (IoT) platform offering. Now in its v2.0 release, the Lumada IoT platform has been fully updated with an elegant, portable architecture that enables it to run both on-premises or in the cloud and to support industrial IoT deployments both at the edge and in the core. The new software stack is designed to help customers quickly and easily gain insights, predictions and recommendations from their data, and can be easily adapted to support mid-to-large-scale environments. Lumada's integrated advanced analytics have also b

Hitachi Introduces Hitachi Vantara: A New Digital Company Committed to Solving the World's Toughest Business and Societal Challenges19.9.2017 17:45Pressmeddelande

Company Formed to Help Customers Achieve Unprecedented Outcomes by Tapping the Full Potential of Their Data TOKYO and LAS VEGAS, Sept.  19, 2017  (GLOBE NEWSWIRE) -- Hitachi, Ltd. (TSE:6501) ("Hitachi") today launched Hitachi Vantara, a new business entity to leverage the broad portfolio of innovation, development and experience from across Hitachi Group companies to deliver data-driven solutions for commercial and industrial enterprises. This new company will unify the operations of Hitachi Data Systems, Hitachi Insight Group, and Pentaho into a single integrated business as Hitachi Vantara to capitalize on Hitachi's social innovation capability in both operational technologies (OT) and information technologies (IT). More Than a Century of OT Expertise Combined with IT Trusted by the World's Largest Enterprises Hitachi has been a leader in OT for industries such as finance, government, manufacturing, power/energy and transportation

Sigma Designs Launches Z-Wave Smart Home Maker Challenge19.9.2017 17:00Pressmeddelande

Sigma Designs and Make: Debut Smart Home Design Mission at World Maker Faire 2017 in New York Celebrating Maker Community Creativity, Collaboration and Inspiring Z-Wave App Design    FREMONT, Calif., Sept. 19, 2017 (GLOBE NEWSWIRE) -- Sigma Designs® (NASDAQ:SIGM), a leading provider of intelligent system-on-chip (SoC) solutions for Connected Smart TV platforms and Smart home IoT, and Make:, leader of the Maker movement and producer of the popular Maker Faire events, today announces a smart home Z-Wave app design contest for Makers and Developers. Sigma Designs launches the Z-Wave Smart Home Maker Challenge today in cooperation with Make: and in unison with the flag-ship World Maker Faire that takes place in New York City September 23-24th. The smart home design competition will be hosted on the all-new Maker Share community platform where participants will have the opportunity to submit their idea for a smart home application that would turn their dream sm

3Gtms Names Managing Director of EMEA19.9.2017 16:00Pressmeddelande

Chris van der Harst will lead growth of unique TMS solution SHELTON, Conn., Sept. 19, 2017 (GLOBE NEWSWIRE) -- 3Gtms, Inc., a global provider of Tier 1 transportation management software (TMS), announced that it has named Chris van der Harst to the new position of managing director, EMEA.   In this position, van der Harst will lead 3Gtms' overseas efforts from its EMEA headquarters in Utrecht, The Netherlands. He will be responsible for growing 3Gtms' market share among 3PLs and mid-large sized shippers, as well as ensuring 3Gtms' industry-leading satisfaction rate is upheld among all customers. 3Gtms' robust TMS gives 3PLs and shippers the most powerful and intuitive system for over-the-road and intermodal freight, along with best-in-class rating and optimization. The modern design enables flexible, seamless handling of the most complicated shipping requirements, covering the complete order-to-cash process. A 30-year supply cha

Novavax Initiates Phase 1/2 Trial of NanoFlu(TM) Vaccine in Older Adults19.9.2017 15:05Pressmeddelande

Recently published NanoFlu(TM) preclinical data provide strong rationale for Phase 1/2 clinical trial based on robust antibody titers and improved protective responses against both current and drifted strains Data from trial expected by the end of 2017 GAITHERSBURG, Md., Sept. 19, 2017 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) today announced the enrollment of the first participant in a Phase 1/2 clinical trial of its nanoparticle influenza vaccine candidate including its proprietary Matrix-M(TM) adjuvant (NanoFlu(TM)) in older adults. The trial is a randomized, observer-blinded, active comparator-controlled trial in approximately 330 healthy older adults. The primary objective of the trial is to assess the safety and immunogenicity of two concentrations (15 µg or 60 µg) of NanoFlu compared to a licensed influenza vaccine, Fluzone® High-Dose (Fluzone HD).

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum